Tulobuterol hydrochloride is a β2-adrenoceptor agonist.

Treatment of the cells with Tulobuterol (0.1 μM) significantly decreases the viral titers of RV14 in the supernatants from 12 h after infection compared with the titers in the cells treated with vehicle (0.001% ethanol). Tulobuterol reduces RV14 release in a concentration-dependent manner. Pretreatment of the cells with Tulobuterol reduces the viral titers of RV14 in the supernatants at concentrations of 0.1 μM or greater[2].

Tulobuterol, a sympathomimetic drug used as a transdermal patch, increases normal diaphragm muscle strength. In vivo effect of Tulobuterol is examined the on the contractility of diaphragm muscles prepared from mice treated with Endotoxin. In the in vivo treatment, E0 and E4 diaphragm muscles are analyzed at 0, 12, and 24 h after transdermal Tulobuterol treatment. The force-frequency curves of E0 and E4 diaphragm muscles at three time points are not significantly changed each other, indicating that Tulobuterol patch restores the muscle contractility. Thus, diaphragm muscle contractility is maintained during 4 h of Endotoxin administration with Tulobuterol patch for over 24 h[3].

[1]. Ebihara S, et al. Cough and transdermal long-acting beta2 agonist in Japan. Respir Med. 2008 Oct;102(10):1497; author reply 1498. [2]. Yamaya M, et al. Tulobuterol inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells. Physiol Rep. 2013 Aug;1(3):e00041. [3]. Shindoh C, et al. Tulobuterol patch maintains diaphragm muscle contractility for over twenty-four hours in a mouse model of sepsis. Tohoku J Exp Med. 2009 Aug;218(4):271-8.